Almost half of people don't wash their hands after using hospital toilets
Researchers at the University of Surrey put sensors on toilet and sink pipes to monitor hygiene behaviours at a hospital in Denmark.
Over the roughly five-month period, they found that 43.7% of users did not wash their hands after using the loo.
The figure, which jumped to 61.8% on some of the weeks, has raised the alarm about hygiene practices that some might have assumed had become commonplace after the pandemic.
Dr Pablo Pereira Doel from the University of Surrey said people failing to wash their hands could 'directly affect patient safety' in hospitals.
People were especially bad at washing their hands at the start and end of the day, as well as during mealtimes.
NHS guidance says hand washing is 'one of the easiest ways to protect yourself and others from illnesses'.
The advice hit the headlines at the start of the pandemic when then-Prime Minister Boris Johnson urged the nation to 'wash your hands for 20 seconds or more'.
Professor Benjamin Gardner, from the University of Surrey, said: 'Strategies that raise awareness at the crucial point in a bathroom visit and easily understood messaging about how to wash effectively – like singing Happy Birthday twice over – can help people form handwashing habits that last.'
The study took place at Bispebjerg hospital in Copenhagen, recording 2,636 over the course of 19 weeks. More Trending
Professor Carrie Newlands, also of the University of Surrey, added the latest findings are 'not surprising'.
'Even simple behaviours like handwashing can lapse without reinforcement.
'In hospitals, lapses like these can have serious consequences – for patients and for the wider healthcare system.
'It's time we moved beyond posters and hand gel stations to more effective behavioural strategies.'
Get in touch with our news team by emailing us at webnews@metro.co.uk.
For more stories like this, check our news page.
MORE: 21 seconds to go: The golden rule for how long it should take you to pee
MORE: The reason why this famous TV doctor travelled 360 miles for surgery
MORE: I'm a millennial – please stop sending me perimenopause memes
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scotsman
19 minutes ago
- Scotsman
Scotland's ‘best and worst' areas to live in 2025 according to new analysis
Scotland's local authority areas have been ranked from 'best to worst' on education, health, community, policing and finance. The analysis, by The Sunday Times, shows huge variation in public service performance across the country. The data shows that some councils are recycling twice as much as others, while in some areas, residents are half as likely to have their first cancer treatment within 62 days as those in other areas. The Sunday Times studied geographical areas covered by each council and the public services provided within those regions. The responsibility for some of those services falls under the remit of different bodies - for example, health services are run by NHS boards. The rankings were compiled using 11 indicators from five key categories – education, health, community, policing and finance. Weighting was applied by population size and the importance of each category, with health and education deemed the most important. Magnus Llewellin, editor of The Times and The Sunday Times Scotland, said 'We all understand that where you live has a huge bearing on your quality of life. But quantifying those differences across areas such as health, education, community and crime isn't readily available for readers. 'That is why the Sunday Times has carried out this analysis across Scotland. It gives people a measure of the differences which, in a number of cases, are stark.' Three councils, Orkney Islands, Shetland Islands and the Western Isles, were excluded from the rankings because of a huge variation in population size and different methods of data collection. Take a look through our gallery to see the huge variation in public service performance across Scotland's local authority areas, as revealed in this analysis by The Sunday Times. 1 . East Renfrewshire - 1st East Renfrewshire is the best council area in Scotland according to The Sunday Times. Education: 1 Health: 4 Community: 1 Crime: 21 Finance: 4 | Google Photo: Google Photo Sales 2 . East Dunbartonshire - 2nd East Dunbartonshire comes in second. Education: 2 Health: 4 Community: 18 Crime: 6 Finance: 5 | Google Photo: Google Photo Sales 3 . South Ayrshire - 3rd Education: 9 Health: 1 Community: 4 Crime: 14 Finance: 9 | Canva/Getty Images Photo Sales 4 . Inverclyde - 4th Education: 7 Health: 4 Community: 17 Crime: 8 Finance: 3 | James / Adobe Stock Photo Sales Related topics: ScotlandNHSCrimeCommunityCouncil
Glasgow Times
23 minutes ago
- Glasgow Times
Thousands of people with debilitating hayfever to benefit from new drug
Betula verrucosa, sold under the brand name Itulazax 12 SQ-Bet and made by Alk-Abello, is an under-the-tongue immunotherapy tablet that contains birch pollen extract. The drug trains the immune system to tolerate tree pollen over three years of daily use. It has been recommended as an option on the NHS for people whose hayfever symptoms persist even after taking antihistamines or using nasal sprays, by the National Institute for Health and Care Excellence (Nice). Severe tree pollen allergies can cause debilitating symptoms for some people during the spring and summer months, including fatigue, breathing difficulties, inflamed sinuses, itchy, watery eyes, and vision changes. Trials show the tablet can significantly reduce the symptoms of severe hayfever by changing how the body responds to allergens. The immunotherapy works by gradually increasing the body's tolerance to tree pollen through controlled daily exposure to small amounts of pollen. Before being given the tablets, patients will require skin prick or blood tests to confirm an allergy to birch tree pollen. Nice estimates that about 27,000 people in England are expected to benefit from the recommendation. Helen Knight, director of medicines evaluation at Nice, said: 'This treatment will help improve people's quality of life. 'Severe tree pollen allergies trap people indoors during beautiful weather and disrupt their work, education and family life. 'The daily tablet offers genuine long-term relief rather than just managing symptoms.' According to Allergy UK, birch pollen allergy is estimated to affect about 25% of hayfever sufferers. Amena Warner, head of clinical services at Allergy UK, said: 'Many people don't realise how awful it is having an itchy, runny nose, sneezing episodes or itchy, irritated eyes in the pollen season. 'We frequently hear from people who avoid time outdoors, keep doors and windows shut, check pollen counts and try and minimise any exposure, which takes a significant toll on their physical and emotional wellbeing. 'Nice's recommendation is so important because it provides a genuine opportunity for people to manage the root cause of their pollen allergy, offering the chance to break free from this burden and enjoy a better quality of life.' Emil Stage Olsen, general manager UK and Republic of Ireland at ALK, added: 'We welcome this positive Nice recommendation, which is another meaningful advancement for the UK allergy community. 'Our focus is now on working closely with the NHS to ensure eligible patients can benefit from this first-in-class immunotherapy.' The NHS in England will provide the treatment within three months of Nice publishing its final guidance.
Rhyl Journal
23 minutes ago
- Rhyl Journal
Thousands of people with debilitating hayfever to benefit from new drug
Betula verrucosa, sold under the brand name Itulazax 12 SQ-Bet and made by Alk-Abello, is an under-the-tongue immunotherapy tablet that contains birch pollen extract. The drug trains the immune system to tolerate tree pollen over three years of daily use. It has been recommended as an option on the NHS for people whose hayfever symptoms persist even after taking antihistamines or using nasal sprays, by the National Institute for Health and Care Excellence (Nice). Severe tree pollen allergies can cause debilitating symptoms for some people during the spring and summer months, including fatigue, breathing difficulties, inflamed sinuses, itchy, watery eyes, and vision changes. Trials show the tablet can significantly reduce the symptoms of severe hayfever by changing how the body responds to allergens. The immunotherapy works by gradually increasing the body's tolerance to tree pollen through controlled daily exposure to small amounts of pollen. Before being given the tablets, patients will require skin prick or blood tests to confirm an allergy to birch tree pollen. Nice estimates that about 27,000 people in England are expected to benefit from the recommendation. Helen Knight, director of medicines evaluation at Nice, said: 'This treatment will help improve people's quality of life. 'Severe tree pollen allergies trap people indoors during beautiful weather and disrupt their work, education and family life. 'The daily tablet offers genuine long-term relief rather than just managing symptoms.' According to Allergy UK, birch pollen allergy is estimated to affect about 25% of hayfever sufferers. Amena Warner, head of clinical services at Allergy UK, said: 'Many people don't realise how awful it is having an itchy, runny nose, sneezing episodes or itchy, irritated eyes in the pollen season. 'We frequently hear from people who avoid time outdoors, keep doors and windows shut, check pollen counts and try and minimise any exposure, which takes a significant toll on their physical and emotional wellbeing. 'Nice's recommendation is so important because it provides a genuine opportunity for people to manage the root cause of their pollen allergy, offering the chance to break free from this burden and enjoy a better quality of life.' Emil Stage Olsen, general manager UK and Republic of Ireland at ALK, added: 'We welcome this positive Nice recommendation, which is another meaningful advancement for the UK allergy community. 'Our focus is now on working closely with the NHS to ensure eligible patients can benefit from this first-in-class immunotherapy.' The NHS in England will provide the treatment within three months of Nice publishing its final guidance.
